Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 401 - 425 of 15603 in total
Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a degree...
Approved
Matched Description: … Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval …
Matched Categories: … Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS...
Approved
Investigational
Matched Iupac: … 1-[2-(2,5-dioxopyrrolidin-1-yl)ethyl] 4-methyl (2E)-but-2-enedioate …
Matched Description: … in October 2019[L9626] and by the EMA in November 2021. ... Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and ... Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as remifentanil, are designed to be metabolically fragile and thus susceptible to rapid...
Approved
Investigational
Matched Iupac: … methyl 3-[(7S)-12-bromo-3-methyl-9-(pyridin-2-yl)-2,5,8-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(14), …
Matched Description: … thus susceptible to rapid biotransformation and elimination as inactive metabolites. ... Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation ... [A214852,A214857] Remimazolam was the first "soft" benzodiazepine analog to be developed[A214862] and
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Benzodiazepines and benzodiazepine derivatives …
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC . It is a third-generation vinca alkaloid. The introduction...
Approved
Investigational
Matched Iupac: … methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10 ... diazatetracyclo[12.3.1.0^{3,11}.0^{4,9}]octadeca-3(11),4,6,8,15-pentaen-12-yl]-10-hydroxy-5-methoxy-8-methyl
Matched Description: … chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma, gastric cancers, non-small cell...
Approved
Investigational
Matched Iupac: … 3-{1-[(3-{5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl}phenyl)methyl]-6-oxo-1,6-dihydropyridazin …
Matched Description: … indirectly, in the growth and proliferation of tumors in which it is overexpressed and/or mutated. ... ] gastric cancers,[A228033] non-small cell lung cancer, and hepatocellular carcinoma. ... [A228058] It was originally developed in partnership between EMD Serono and the University of Texas M.D …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Nilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension.
Approved
Investigational
Matched Iupac: … 3-methyl 5-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate …
Matched Categories: … Calcium-Regulating Hormones and Agents …
Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in heparin and HS...
Approved
Investigational
Matched Iupac: … ]oxan-2-yl]oxy}-3,4-dihydroxyoxan-2-yl]oxy}-3-(sulfoamino)-4-(sulfooxy)-6-[(sulfooxy)methyl]oxan-2-yl ... 5R,6R)-5-{[(2R,3R,4R,5S,6S)-6-carboxy-5-{[(2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfoamino)-6-[(sulfooxy)methyl ... ]oxy}-4-hydroxy-6-{[(2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfoamino)-2-[(sulfooxy)methyl]oxan-3-yl …
Matched Description: … a O-methyl group at the reducing end of the molecule. ... Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and ... It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they …
Matched Categories: … Blood and Blood Forming Organs …
Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Approved
Matched Description: … It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the …
Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, activating the enzyme guanylate cyclase and increasing the...
Approved
Matched Iupac: … 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propyl-1H,4H-imidazo[4,3-f][1,2,4]triazin …
Matched Description: … [L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial ... selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and ... cells in the corpus cavernosum, activating the enzyme guanylate cyclase and increasing the synthesis …
Matched Categories: … Genito Urinary System and Sex Hormones …
A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed)
Approved
Matched Iupac: … (4R,7R)-N-[(2S)-1-hydroxybutan-2-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1 …
Matched Categories: … Ergot Alkaloids and Derivatives ... methylergometrine and oxytocin ... Genito Urinary System and Sex Hormones …
Avacincaptad pegol is an RNA aptamer covalently bound to a branched polyethylene glycol (PEG) molecule. It was developed to treat an advanced form of age-related macular degeneration (AMD) called geographic atrophy (GA). AMD is the leading cause of vision loss in developed countries for people over 50 years old, with...
Approved
Investigational
Matched Description: … Avacincaptad pegol is an RNA aptamer covalently bound to a branched polyethylene glycol (PEG) molecule ... AMD eventually progresses to bilateral and irreversible loss of vision, whether or not the patients have ... This approval is based on the positive results obtained from 2 phase 3 clinical trials GATHER1 and GATHER2 …
A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from aspartic acid and ammonia by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed)
Approved
Investigational
Nutraceutical
Matched Description: … (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed) ... It is biosynthesized from aspartic acid and ammonia by asparagine synthetase. ... A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows this agent to...
Approved
Illicit
Matched Iupac: … 2-methyl-1-phenylpropan-2-amine …
Matched Description: … Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity ... [A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical ... [A174367] Phentermine was FDA approved for short-term weight management in 1959 and it became widely …
Matched Categories: … Alimentary Tract and Metabolism ... phentermine and topiramate …
A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.
Approved
Investigational
Matched Categories: … Antiglaucoma Preparations and Miotics …
A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868)
Approved
Matched Description: … (From Smith and Reynard, Textbook of Pharmacology, 1992, p868) …
A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.
Approved
Illicit
Vet approved
A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.
Approved
Matched Description: … It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid …
Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the...
Approved
Investigational
Matched Description: … rheumatoid arthritis and osteoarthritis. ... Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. ... Diflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of …
Matched Categories: … Salicylic Acid and Derivatives …
Finasteride is a synthetic 4-azasteroid compound and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). It works in a similar fashion as dutasteride, which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects. Finasteride is an orally active drug...
Approved
Matched Description: … Finasteride is a synthetic 4-azasteroid compound [L10565] and specific inhibitor of steroid Type II 5α-reductase ... [L6244] Finasteride is commonly marketed under the brand names Propecia and Proscar to be used aloneo ... first approved by the FDA in 1992 for the treatment of benign prostatic hyperplasia to improve symptoms and
Matched Categories: … doxazosin and finasteride ... alfuzosin and finasteride ... finasteride and tadalafil ... Skin and Mucous Membrane Agents ... Genito Urinary System and Sex Hormones …
Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal secretion....
Approved
Matched Description: … and combination hormone replacement therapy generally offers no therapeutic advantage. ... It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in ... It is now known that the thyroid gland secretes approximately ten times more T4 than T3 and that 80% …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Approved
Experimental
Investigational
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is...
Approved
Investigational
Matched Iupac: … (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-(2-methyl-1,3-thiazol-4- …
Matched Description: … Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Cytotoxic Antibiotics and Related Substances …
Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates. Intravenous formulation was approved in Europe in September 2010 as Brinavess and...
Approved
Investigational
Matched Description: … Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April …
Matched Categories: … Methyl Ethers …
Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a...
Approved
Investigational
Matched Description: … associated with Parkinson's disease , pure autonomic failure, and multiple system atrophy, and is the ... It is approved for use in Japan and is currently in trials in the U.S. ... The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated …
Matched Categories: … Epinephrine and similars ... Adrenergic and Dopaminergic Agents ... Amino Acids, Peptides, and Proteins …
Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Approved
Displaying drugs 401 - 425 of 15603 in total